US11504386B2 - Preparation method for various novel fucosyl oligosaccharides and use thereof - Google Patents

Preparation method for various novel fucosyl oligosaccharides and use thereof Download PDF

Info

Publication number
US11504386B2
US11504386B2 US16/765,359 US201816765359A US11504386B2 US 11504386 B2 US11504386 B2 US 11504386B2 US 201816765359 A US201816765359 A US 201816765359A US 11504386 B2 US11504386 B2 US 11504386B2
Authority
US
United States
Prior art keywords
fucosyl
fucose
gdp
fucosyltransferase
oligosaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US16/765,359
Other versions
US20200338101A1 (en
Inventor
Kyoung Heon Kim
Yong-Su Jin
Eun-Ju Yun
Sora YU
Jaewon Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea University Research and Business Foundation
Original Assignee
Korea University Research and Business Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea University Research and Business Foundation filed Critical Korea University Research and Business Foundation
Assigned to KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION reassignment KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JIN, YONG-SU, KIM, KYOUNG HEON, LEE, JAEWON, YU, Sora, YUN, Eun-Ju
Publication of US20200338101A1 publication Critical patent/US20200338101A1/en
Application granted granted Critical
Publication of US11504386B2 publication Critical patent/US11504386B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/729—Agar; Agarose; Agaropectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/18—Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01069—Galactoside 2-alpha-L-fucosyltransferase (2.4.1.69)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a method of producing various novel fucosyl-oligosaccharides through an enzymatic reaction with ⁇ -1,2-fucosyltransferase using a GDP-L-fucose donor and various sugar acceptors, and a use thereof as a prebiotic.
  • Prebiotics refer to substances that are selectively fermented by beneficial intestinal bacteria to improve intestinal flora and are beneficial to human health. Recently, studies on the correlation between human diseases and intestinal flora have been reported, and intestinal flora is recognized as the second human genome, and thus research in this field is rapidly developing. In particular, as study results have been reported, showing that obesity, diabetes, and immune function are improved according to an increase in the distribution of beneficial intestinal flora, research on intestinal flora is receiving more attention.
  • Fucosyl-oligosaccharides are one of the main components of breast milk oligosaccharides and have activity of prebiotics selectively fermented by probiotic microorganisms and physiological activity that prevents intestinal settlement of pathogenic microorganisms. In addition to intestinal health-related physiological activity, fucosyl-oligosaccharides are known to enhance memory and are expected to help prevent dementia.
  • fucosyl-oligosaccharides it is known that fucosylgalactose (FGal), which is a disaccharide, promotes the growth of nerve cells when hippocampal neurons, which are brain neural cells, are treated therewith. This suggests the possibility that FGal can be used as an agent for treating nervous system-related diseases such as Alzheimer's disease or Parkinson's disease.
  • FGal fucosylgalactose
  • Alzheimer's disease As population aging rapidly progresses worldwide, the number of patients with neurological diseases such as Alzheimer's disease or Parkinson's disease is rapidly increasing, and accordingly, demand for developing effective therapeutic agents is increasing. For example, the global market for Alzheimer's disease therapeutics is expected to expand to $13.3 billion by 2023, and the market for Parkinson's disease therapeutics is expected to expand to $4.7 billion by 2022.
  • drugs for alleviating symptoms have been mainly developed, and thus there is no drug for fundamental treatment such that all demands cannot be met, and accordingly, the potential market is expected to greatly expand.
  • the expansion of purchasing power in the third world, such as Southeast Asia due to economic growth is expected to contribute to market growth in the future.
  • An object of the present invention is to provide a method of producing various fucosyl-oligosaccharides through the enzymatic reaction of ⁇ -1,2-fucosyltransferase with a GDP-L-fucose donor and various sugar acceptors.
  • Another object of the present invention is to provide a use of fucosyl-oligosaccharides having prebiotic properties.
  • a prebiotic pharmaceutical composition including one or more fucosyl-oligosaccharides selected from the group consisting of 2′-fucosylglucose, 2′-fucosylgalactose, 2′-fucosylcellobiose, 2′-fucosylfructose, 2′-fucosylsucrose, 2′-fucosylmaltose, 2′-fucosylmannose, 2′-fucosylxylose, and 2′-fucosylagarobiose.
  • fucosyl-oligosaccharides selected from the group consisting of 2′-fucosylglucose, 2′-fucosylgalactose, 2′-fucosylcellobiose, 2′-fucosylfructose, 2′-fucosylsucrose, 2′-fucosylmaltose, 2′-fucosylmannose, 2′-fucosylxylose, and 2
  • the present invention also provides a method of improving the intestinal health of a subject, including administering the prebiotic pharmaceutical composition to the subject.
  • the present invention also provides a prebiotic cosmetic composition including one or more fucosyl-oligosaccharides selected from the group consisting of 2′-fucosylglucose, 2′-fucosylgalactose, 2′-fucosylcellobiose, 2′-fucosylfructose, 2′-fucosylsucrose, 2′-fucosylmaltose, 2′-fucosylmannose, 2′-fucosylxylose, and 2′-fucosylagarobiose.
  • fucosyl-oligosaccharides selected from the group consisting of 2′-fucosylglucose, 2′-fucosylgalactose, 2′-fucosylcellobiose, 2′-fucosylfructose, 2′-fucosylsucrose, 2′-fucosylmaltose, 2′-fucosylmannose, 2′-fucosylx
  • the present invention also relates to a prebiotic food composition including one or more fucosyl-oligosaccharides selected from the group consisting of 2′-fucosylglucose, 2′-fucosylgalactose, 2′-fucosylcellobiose, 2′-fucosylfructose, 2′-fucosylsucrose, 2′-fucosylmaltose, 2′-fucosylmannose, 2′-fucosylxylose, and 2′-fucosylagarobiose.
  • fucosyl-oligosaccharides selected from the group consisting of 2′-fucosylglucose, 2′-fucosylgalactose, 2′-fucosylcellobiose, 2′-fucosylfructose, 2′-fucosylsucrose, 2′-fucosylmaltose, 2′-fucosylmannose, 2′-fucosy
  • the present invention also provides a method of producing a fucosyl-oligosaccharide, including reacting a sugar acceptor and a guanosine 5′-diphospho- ⁇ -L-fucose (GDP-L-fucose) donor with ⁇ -1,2-fucosyltransferase to produce a fucosyl-oligosaccharide,
  • GDP-L-fucose guanosine 5′-diphospho- ⁇ -L-fucose
  • the sugar acceptor includes one or more selected from the group consisting of glucose, galactose, cellobiose, lactose, fructose, sucrose, maltose, mannose, xylose, and agarobiose, and
  • the ⁇ -1,2-fucosyltransferase includes any one selected from the amino acid sequences of SEQ ID NOS: 1 to 3.
  • the present invention also provides a method of producing a fucosyl-oligosaccharide, including: culturing, in the presence of a sugar acceptor and glycerol, recombinant E. coli or yeast into which a vector for expressing ManB, ManC, Gmd, and WcaG involved in the de novo pathway for producing a guanosine 5′-diphospho- ⁇ -L-fucose (GDP-L-fucose) donor; and a vector for expressing ⁇ -1,2-fucosyltransferase are introduced; and separating and purifying a fucosyl-oligosaccharide from the E. coli culture,
  • the sugar acceptor includes one or more selected from the group consisting of glucose, galactose, cellobiose, lactose, fructose, sucrose, maltose, mannose, xylose, and agarobiose, and
  • the ⁇ -1,2-fucosyltransferase includes any one selected from the amino acid sequences of SEQ ID NOS: 1 to 3.
  • the present invention has the effect of providing a method of producing a fucosyl-oligosaccharide using the enzymatic reaction of a GDP-L-fucose donor and various sugar acceptors with ⁇ -1,2-fucosyltransferase or by applying the enzymatic reaction to a metabolic engineering technique in recombinant E. coli.
  • the present invention also provides the effect of fucosyl-oligosaccharides to be used as prebiotic materials in medical, cosmetic, and food fields based on the prebiotic properties thereof.
  • FIG. 1 is a view illustrating the production of various types of fucosyl-oligosaccharides using a GDP-fucose donor and various sugar acceptors through the enzymatic reaction of ⁇ -1,2-fucosyltransferase.
  • FIG. 2 illustrates test results showing the reactivity between ⁇ -1,2-fucosyltransferase and various sugar acceptors.
  • FIGS. 3 to 5 illustrate LC/MS analysis results of fucosyl-oligosaccharides produced through the enzymatic reaction with ⁇ -1,2-fucosyltransferase using a GDP-L-fucose donor and sugar acceptors such as glucose, galactose, cellobiose, lactose, fructose, sucrose, maltose, mannose, xylose, and agarobiose.
  • a GDP-L-fucose donor and sugar acceptors such as glucose, galactose, cellobiose, lactose, fructose, sucrose, maltose, mannose, xylose, and agarobiose.
  • FIG. 6 illustrates a view for producing 2-fucosylgalactose using recombinant E. coli (A), and batch fermentation results (B) and fed-batch fermentation results (C) of recombinant E. coli.
  • FIG. 7 illustrates 2-fucosylgalactose (B) separated and purified by size-exclusion chromatography using a G-10 column in a fermentation broth of recombinant E. coli (A), results of the enzymatic reaction of ⁇ -1,2-fucosyltransferase using 2-fucosylgalactose as a substrate to confirm the ⁇ -1,2-glycosidic bond of 2-fucosylgalactose (D), and results of the enzymatic reaction of ⁇ -1,2-fucosidase of a crude enzyme solution of recombinant E. coli including, as a control, an empty vector free of a gene encoding the enzyme (C).
  • FIG. 8 illustrates the results of confirming the prebiotic activity of 2-fucosylgalactose in a strain belonging to the genus Bifidobacterium.
  • FIG. 9 illustrates the results of confirming the metabolism of 2-fucosylgalactose in pathogenic microorganisms.
  • FGal fucosylgalactose
  • Bifidobacter which is a probiotic microorganism.
  • agarobiose which is a disaccharide basic structure constituting agarose, a major carbohydrate of red algae, was used to first produce 2-fucosylagarobiose.
  • Agarobiose is known as a bioactive substance with antioxidant, antimicrobial, anti-inflammatory, and anticancer effects, and 2-fucosylagarobiose produced through the fucosylation reaction is a new material and is also expected to be a material with various physiological activities.
  • the present invention relates to a prebiotic pharmaceutical composition including one or more fucosyl-oligosaccharides selected from the group consisting of 2′-fucosylglucose, 2′-fucosylgalactose, 2′-fucosylcellobiose, 2′-fucosylfructose, 2′-fucosylsucrose, 2′-fucosylmaltose, 2′-fucosylmannose, 2′-fucosylxylose, and 2′-fucosylagarobiose.
  • fucosyl-oligosaccharides selected from the group consisting of 2′-fucosylglucose, 2′-fucosylgalactose, 2′-fucosylcellobiose, 2′-fucosylfructose, 2′-fucosylsucrose, 2′-fucosylmaltose, 2′-fucosylmannose, 2′-fucosyl
  • the fucosyl-oligosaccharide(s) are prebiotics that promote the proliferation of beneficial intestinal bacteria, inhibit the growth of harmful intestinal bacteria, and are not metabolized by pathogenic microorganisms. In addition, by binding to the adhesion sites or receptor sites of Salmonella, Helicobacter , Pathogenic E. coli , Norovirus, and the like, the fucosyl-oligosaccharide(s) may also prevent pathogenic bacteria and viruses from infecting the human body and proliferating.
  • 2-fucosylgalactose may be used as a therapeutic agent for neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease through promotion of the growth of nerve cells
  • 2-fucosylagarobiose can also be used as antioxidant, antibacterial, anti-inflammatory, and anticancer agents due to properties of agarobiose itself, such as antioxidant, antibacterial, anti-inflammatory, and anticancer properties.
  • Bifidobacterium longum subsp. infantis ATCC 15697 decomposes 2-fucosylgalactose into galactose and fucose through intracellular fucosidase and uses both
  • Bifidobacterium bifidum DSM 20082 extracellularly decomposes 2-fucosylgalactose into galactose and fucose, and then uses only galactose.
  • coli which causes urinary tract infections, neonatal meningitis, and septicemia
  • Salmonella enterica serovar typhimurium which causes diarrhea and bacteremia, are unable to metabolize 2-fucosylgalactose and are prebiotics selectively fermented only by probiotic microorganisms.
  • the fucosyl-oligosaccharide(s) may be produced by reacting a sugar acceptor and a guanosine 5′-diphospho- ⁇ -L-fucose (GDP-L-fucose) donor with ⁇ -1,2-fucosyltransferase.
  • GDP-L-fucose guanosine 5′-diphospho- ⁇ -L-fucose
  • recombinant E recombinant E.
  • coli or yeast into which a vector for expressing ManB, ManC, Gmd, and WcaG involved in the de novo pathway for producing GDP-L-fucose; and a vector for expressing ⁇ -1,2-fucosyltransferase are introduced may be cultured in the presence of a sugar acceptor and glycerol, respectively, and fucosyl-oligosaccharide(s) may be obtained from the culture by separation and purification.
  • the term “beneficial intestinal bacteria” has the same meaning as “probiotics” and refers to strains that have a beneficial effect on the intestinal environment when ingested and reaching the intestine, and means bacteria that survive in stomach acid and bile acid to reach the small intestine and consequently, proliferate and settle in the intestine, have a beneficial effect in the intestinal tract, and satisfy conditions such as no toxicity and non-pathogenicity.
  • the beneficial intestinal bacteria include bacteria belonging to the genus Lactobacillus , the genus Lactococcus , the genus Enterococcus , the genus Streptococcus , and the genus Bifidobacterium .
  • the beneficial intestinal bacteria are strains belonging to the genus Bifidobacterium , the genus Lactobacillus , or the genus Streptococcus , more particularly strains belonging to the genus Bifidobacterium or the genus Streptococcus .
  • the strain belonging to the genus Bifidobacterium according to the present invention includes Bifidobacterium longum subsp. infantis ATCC 15697, Bifidobacterium bifidum DSM 20082, or Bifidobacterium kashiwanohence DSM 21854.
  • the strain belonging to the genus Lactobacillus includes Lactobacillus reuteri
  • the strain belonging to the genus Streptococcus includes Streptococcus thermophilus.
  • the term “harmful intestinal bacteria” refers to strains that have an adverse effect on the intestinal environment when ingested and reaching the intestine.
  • the harmful intestinal bacteria include strains belonging to the genus Pseudomonas - aeruginosa , the genus Vibrio , the genus Staphylococcus , the genus Clostridium perfringens , the genus Eubacterium , and the genus Bacteroides , and sulfate reducers.
  • the harmful intestinal bacteria are strains belonging to the genus Clostridium perfringens , the genus Eubacterium , or the genus Bacteroides .
  • the strain belonging to the genus Clostridium perfringens includes Clostridium difficile or Clostridium perfringens .
  • the strain belonging to the genus Eubacterium includes Eubacterium limosum
  • the strain belonging to the genus Bacteroides includes Bacteroides fragilis.
  • the prebiotic pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carrier includes carriers and vehicles commonly used in the medical field, and particularly, includes ion exchange resins, alumina, aluminum stearate, lecithin, serum proteins (e.g., human serum albumin), buffer substances (e.g., various phosphates, glycine, sorbic acid, potassium sorbate, and partial glyceride mixtures of saturated vegetable fatty acids), water, salts or electrolytes (e.g., protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, and zinc salts), colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substrates, polyethylene glycol, sodium carboxymethylcellulose, polyarylates, wax, polyethylene glycol, or lanolin, but the present invention is not limited thereto.
  • the prebiotic pharmaceutical composition of the present invention may further include, in addition to the above-described ingredients, a lubricant, a wetting agent, an emulsifying agent, a suspension agent, a preservative, or the like.
  • the prebiotic pharmaceutical composition of the present invention may be formulated and used in the form of various preparations suitable for oral administration or parenteral administration.
  • Non-limiting examples of the preparations for oral administration include troches, lozenges, tablets, aqueous suspensions, oily suspensions, prepared powders, emulsions, hard capsules, soft capsules, syrups, and elixirs.
  • a binder such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose, gelatin, or the like; an excipient such as dicalcium phosphate or the like; a disintegrant such as corn starch, sweet potato starch, or the like; a lubricant such as magnesium stearate, calcium stearate, sodium stearyl fumarate, polyethylene glycol wax, or the like; or the like may be used, and a sweetener, a fragrance, syrup, or the like may also be used.
  • a binder such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose, gelatin, or the like
  • an excipient such as dicalcium phosphate or the like
  • a disintegrant such as corn starch, sweet potato starch, or the like
  • a lubricant such as magnesium stearate, calcium
  • a liquid carrier such as a fatty oil, and the like may be further used in addition to the aforementioned materials.
  • Non-limiting examples of the preparations for parenteral administration may include injections, suppositories, respiratory inhalation powders, spray aerosols, oral sprays, mouthwashes, toothpastes, ointments, powders for application, oils, and creams.
  • aqueous solutions sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, agents for external application, or the like may be used, and as the non-aqueous solvents and the suspensions, propylene glycol, polyethylene glycol, a vegetable oil such as olive oil, an injectable ester such as ethyl oleate, or the like may be used.
  • the prebiotic pharmaceutical composition of the present invention when the prebiotic pharmaceutical composition of the present invention is formulated into an injection, the prebiotic pharmaceutical composition of the present invention is mixed with a stabilizer or a buffer in water to prepare a solution or a suspension, followed by preparation into an ampoule or vial unit dosage form.
  • a propellant or the like for dispersing a water-dispersed concentrate or wet powder may be blended with an additive.
  • the prebiotic pharmaceutical composition of the present invention when formulated into an ointment, a cream, or the like, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, a cellulose derivative, polyethylene glycol, silicon, bentonite, silica, talc, zinc oxide, or the like may be used as a carrier.
  • a pharmaceutically effective amount and effective dosage level of the prebiotic pharmaceutical composition of the present invention may vary depending on formulation methods, administration methods, administration time, and/or administration route of the composition, and may vary depending on various factors including the type and degree of reaction to be achieved via administration of the prebiotic pharmaceutical composition of the present invention, the type, age, and body weight of an individual to which the composition is administered, general health condition, the symptoms or severity of disease, gender, diet, excretion, drugs used simultaneously or at different times in the corresponding individual, components of other compositions, and the like, and similar factors well known in the medical field, and one of ordinary skill in the art can determine and prescribe an effective dose for targeted treatment.
  • the prebiotic pharmaceutical composition of the present invention may be administered once a day or in multiple doses. Thus, the effective dose is not intended to limit the scope of the present invention in any way.
  • the administration route and administration method of the prebiotic pharmaceutical composition of the present invention may be independent from each other, the administration method is not particularly limited, and the administration route and the administration method may be an arbitrary administration route and administration route as long as they enable the prebiotic pharmaceutical composition to reach the corresponding site.
  • the prebiotic pharmaceutical composition may be administered orally or parenterally.
  • parenteral administration may be, for example, intravenous administration, intraperitoneal administration, intramuscular administration, transdermal administration, subcutaneous administration, or the like, and the prebiotic pharmaceutical composition may be applied or sprayed on a diseased site, or inhaled, but the present invention is not limited thereto.
  • the prebiotic pharmaceutical composition of the present invention may preferably be administered orally or by injection.
  • the present invention also provides a method of improving the intestinal health of a subject, including administering the prebiotic pharmaceutical composition to the subject.
  • the method of improving the intestinal health according to the present invention includes treating heartburn, indigestion, abdominal bloating, diarrhea, constipation, gas, or the like.
  • subject means all animals including mammals including mice, livestock, humans, and the like.
  • the present invention also provides a prebiotic cosmetic composition including one or more fucosyl-oligosaccharides selected from the group consisting of 2′-fucosylglucose, 2′-fucosylgalactose, 2′-fucosylcellobiose, 2′-fucosylfructose, 2′-fucosylsucrose, 2′-fucosylmaltose, 2′-fucosylmannose, 2′-fucosylxylose, and 2′-fucosylagarobiose.
  • fucosyl-oligosaccharides selected from the group consisting of 2′-fucosylglucose, 2′-fucosylgalactose, 2′-fucosylcellobiose, 2′-fucosylfructose, 2′-fucosylsucrose, 2′-fucosylmaltose, 2′-fucosylmannose, 2′-fucosylx
  • Oligosaccharides including fucose may exhibit functionality that thickens the skin epidermal layer to alleviate wrinkles. Therefore, in consideration of skin permeability and absorption rate, fucosyl-oligosaccharides may exhibit excellent anti-wrinkle activity.
  • fucosyl-oligosaccharides 2′-fucosylagarobiose can be effectively used to inhibit or treat atopy, acne, dandruff, and the like through the antioxidant and antibacterial activities of agarobiose itself.
  • the cosmetic composition of the present invention includes: water-soluble vitamins such as vitamin B1, vitamin B2, vitamin B6, pyridoxine, pyridoxine hydrochloride, vitamin B12, pantothenic acid, nicotinic acid, nicotinic acid amide, folic acid, vitamin C, vitamin H, and the like; oil-soluble vitamins such as vitamin A, carotene, vitamin D2, vitamin D3, vitamin E (d1-alpha tocopherol, d-alpha tocopherol, d-alpha tocopherol), and the like; polymer peptides such as collagen, hydrolyzed collagen, gelatin, elastin, hydrolyzed elastin, keratin, and the like; polymeric polysaccharides such as hydroxyethyl cellulose, xanthan gum, sodium hyaluronate, chondroitin sulfate or salts thereof (sodium salts and the like), and the like; sphingolipids such as ceramide,
  • the cosmetic composition of the present invention may include, in addition to the above essential ingredients, other ingredients mixed in general cosmetics as necessary.
  • Other mixed ingredients that may be added may include oil and fat ingredients, a moisturizing agent, an emollient agent, a surfactant, organic and inorganic pigments, organic powders, an ultraviolet absorbent, a preservative, a bactericide, an antioxidant, a plant extract, a pH adjusting agent, alcohols, dyes, pigments, a blood circulation promoter, a cooling agent, an antiperspirant, purified water, and the like.
  • Oil and fat ingredients may include ester-based oil and fat, hydrocarbon-based oil and fat, silicone-based oil and fat, fluorine-based oil and fat, animal oil and fat, vegetable oil and fat, and the like.
  • mixed ingredients that may be added are not limited to the above examples, and may be mixed within a range that does not adversely affect the objects and effects of the present invention.
  • the cosmetic composition of the present invention may be in the form of a solution, an emulsion, a viscous mixture, or the like.
  • the ingredients included in the cosmetic composition of the present invention may include ingredients commonly used in cosmetic compositions as active ingredients, and include, for example, general adjuvants and carriers such as a stabilizer, a solubilizer, vitamins, a pigment, and a flavor.
  • general adjuvants and carriers such as a stabilizer, a solubilizer, vitamins, a pigment, and a flavor.
  • the cosmetic composition of the present invention may be prepared into any form generally prepared in the art, and examples thereof include a skin lotion, a skin softener, a skin toner, a milk lotion, an astringent, a lotion, a moisturizing lotion, a nourishing lotion, a massage cream, a nourishing cream, a moisturizing cream, a hand cream, a foundation, an essence, a nourishing essence, a pack, a soap, a cleansing foam, a cleansing lotion, a cleansing cream, a hair lotion, a hair tonic, a hair essence, a hair shampoo, a hair rinse, a hair treatment, a body lotion, and a body cleanser.
  • the present invention also provides a prebiotic food composition including one or more fucosyl-oligosaccharides selected from the group consisting of 2′-fucosylglucose, 2′-fucosylgalactose, 2′-fucosylcellobiose, 2′-fucosylfructose, 2′-fucosylsucrose, 2′-fucosylmaltose, 2′-fucosylmannose, 2′-fucosylxylose, and 2′-fucosylagarobiose.
  • fucosyl-oligosaccharides selected from the group consisting of 2′-fucosylglucose, 2′-fucosylgalactose, 2′-fucosylcellobiose, 2′-fucosylfructose, 2′-fucosylsucrose, 2′-fucosylmaltose, 2′-fucosylmannose, 2′-fucosylx
  • the food composition of the present invention may be used as a health functional food, a food additive, or a dietary supplement.
  • the fucosyl-oligosaccharide(s) When used as a food additive, the fucosyl-oligosaccharide(s) may be appropriately used according to a general method such as being added directly or mixed in combination with other foods or food ingredients.
  • the amount of fucosyl-oligosaccharide(s) to be mixed may be appropriately changed according to the purpose of use (prevention, health or therapeutic treatment), and ranges from preferably 0.01 wt % to 95 wt %, more preferably 0.1 wt % to 80 wt %, with respect to a total weight of the food composition.
  • the amount is less than 0.01 wt %, dose efficiency may be lowered, and when the amount is greater than 95 wt %, there may be difficulties in formulation.
  • the fucosyl-oligosaccharide(s) of the present invention when prepared into a food or a beverage, are added in an amount of 15 wt % or less, preferably 10 wt % or less, with respect to a total weight of raw materials.
  • the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may also be used in an amount above the above range.
  • the type of the food is not particularly limited, but examples of foods to which the fucosyl-oligosaccharide(s) of the present invention may be added include meats, sausages, bread, chocolates, candies, snacks, confectionaries, pizzas, instant noodles, other noodles, gums, dairy products including ice creams, various kinds of soup, beverages, teas, drinks, alcoholic drinks, vitamin complexes, and the like, and all health foods in the ordinary sense are included.
  • the food composition of the present invention may include additional ingredients such as various flavor enhancers or natural carbohydrates like general beverages.
  • natural carbohydrates monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; natural sweeteners such as dextrin and cyclodextrin; and synthetic sweeteners such as saccharin and aspartame may be used.
  • the natural carbohydrate is included in an amount of 0.01 wt % to 10 wt %, preferably 0.01 wt % to 0.1 wt %, with respect to the total weight of the food composition of the present invention.
  • the food composition of the present invention may include various nutritional supplements, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, a protective colloid thickener, a pH adjuster, a stabilizer, a preservative, glycerin, alcohols, a carbonating agent used in carbonated beverages, and the like, and may include flesh for the preparation of natural fruit juice, fruit juice beverages, and vegetable beverages, but the present invention is not limited thereto.
  • These ingredients may be used alone or a combination thereof may be used.
  • the proportion of these additives is not particularly limited, but may range from 0.01 wt % to 0.1 wt % with respect to the total weight of the food composition of the present invention.
  • the food composition of the present invention may be ingested for a long period of time since there is no problem in terms of safety.
  • the present invention also provides a method of producing a fucosyl-oligosaccharide, including reacting a sugar acceptor and a guanosine 5′-diphospho- ⁇ -L-fucose (GDP-L-fucose) donor with ⁇ -1,2-fucosyltransferase to produce a fucosyl-oligosaccharide,
  • GDP-L-fucose guanosine 5′-diphospho- ⁇ -L-fucose
  • the sugar acceptor includes one or more selected from the group consisting of glucose, galactose, cellobiose, lactose, fructose, sucrose, maltose, mannose, xylose, and agarobiose, and
  • the ⁇ -1,2-fucosyltransferase includes any one selected from the amino acid sequences of SEQ ID NOS: 1 to 3.
  • a fucosyl-oligosaccharide by reacting a sugar acceptor and a GDP-L-fucose donor with ⁇ -1,2-fucosyltransferase, a fucosyl-oligosaccharide, not a derivatized form, can be produced.
  • a fucosyl-oligosaccharide not a derivatized form
  • it is possible to produce various types of fucosyl-oligosaccharides using various sugar acceptors see FIG. 1 ).
  • the sugar acceptor may be selected from the group consisting of glucose, galactose, cellobiose, lactose, fructose, sucrose, maltose, mannose, xylose, and agarobiose.
  • the ⁇ -1,2-fucosyltransferase may be derived from Helicobacter pylori, Bacteroides fragilis, E. coli O126, or the like, and particularly, may include any one selected from the amino acid sequences of SEQ ID NOS: 1 to 3.
  • the ⁇ -1,2-fucosyltransferase showed a difference in reactivity according to the type of sugar acceptor.
  • Bacteroides fragilis -derived WcfB exhibited high activity for cellobiose, galactose, and glucose
  • E. coli O126-derived WbgL exhibited high activity for lactose and galactose
  • Helicobacter pylori -derived FucT2 exhibited high activity for cellobiose and galactose.
  • the enzymatic reaction of the sugar acceptor and the GDP-L-fucose donor with ⁇ -1,2-fucosyltransferase may be performed at 20° C. to 40° C. for 3 hours to 24 hours, more particularly at 25° C. to 35° C. for 6 hours to 12 hours.
  • a fucosyl-oligosaccharide produced by the method of producing a fucosyl-oligosaccharide according to the present invention may be 2′-fucosylglucose, 2′-fucosylgalactose, 2′-fucosylcellobiose, 2′-fucosyllactose, 2′-fucosylfructose, 2′-fucosylsucrose, 2′-fucosylmaltose, 2′-fucosylmannose, 2′-fucosylxylose, or 2′-fucosylagarobiose.
  • the present invention also provides a method of producing a fucosyl-oligosaccharide, including: culturing, in the presence of a sugar acceptor and glycerol, recombinant E. coli or yeast into which a vector for expressing ManB, ManC, Gmd, and WcaG involved in the de novo pathway for producing a guanosine 5′-diphospho- ⁇ -L-fucose (GDP-L-fucose) donor; and a vector for expressing ⁇ -1,2-fucosyltransferase are introduced; and separating and purifying a fucosyl-oligosaccharide from the E. coli culture,
  • the sugar acceptor includes one or more selected from the group consisting of glucose, galactose, cellobiose, lactose, fructose, sucrose, maltose, mannose, xylose, and agarobiose, and
  • the ⁇ -1,2-fucosyltransferase includes any one selected from the amino acid sequences of SEQ ID NOS: 1 to 3.
  • 2-fucosyllactose which is a fucosyl-oligosaccharide
  • 2-fucosyllactose is produced from lactose using Helicobacter -derived fucosyltransferase, but it is disadvantageous in that it is not possible to produce various fucosyl-oligosaccharides.
  • various types of fucosyl-oligosaccharides may be produced through microbial fermentation by employing a microorganism metabolic engineering technique, and to this end, E. coli or yeast in which the metabolic pathway of a material used as a sugar acceptor is deleted is used as a host, the de novo pathway is introduced into the host to produce GDP-1-fucose as a donor, a sugar substance is supplied as an acceptor, glycerol is used as a carbon source, and ⁇ -1,2-fucosyltransferase is introduced, thereby producing fucosyl-oligosaccharides through fermentation. Therefore, the method of the present invention may include:
  • a vector for expressing ManB, ManC, Gmd, and WcaG involved in the de novo pathway for producing, as a donor, guanosine 5′-diphospho- ⁇ -L-fucose (GDP-L-fucose) in E. coli , and a vector for expressing ⁇ -1,2-fucosyltransferase;
  • the de novo pathway for producing GDP-L-fucose is a pathway in which, by using fructose 6P as a starting material and mannose-6-phosphate isomerase (ManM), phosphomannomutase (ManB), mannose-1-phosphate guanosyltransferase (ManC), GDP-mannose-4,6-dehydratase (Gmd), and GDP-L-fucose synthase (WcaG), intermediate products such as mannose 6P, mannose 1P, GDP-D-mannose, and GDP-4-keto-6-deoxymannose are sequentially produced, and finally, GDP-L-fucose is produced.
  • ManM mannose-6-phosphate isomerase
  • ManB mannose-1-phosphate guanosyltransferase
  • Gmd GDP-mannose-4,6-dehydratase
  • WcaG GDP-L-fucose synthase
  • the culture of the transformed E. coli may include fed-batch culture.
  • the fed-batch culture may be performed at 25° C. to 37° C. for 2 hours to 60 hours, and isopropyl ⁇ -D-1-thiogalactopyranoside (IPTG) may be added and the fed-batch culture may be performed at 20° C. to 30° C. for 60 hours to 150 hours.
  • IPTG isopropyl ⁇ -D-1-thiogalactopyranoside
  • E. coli -derived WbgL (GenBank: ABE98421.1), Helicobacter pylori -derived FucT2 (GenBank: AAC99764.1), and WcfB (GenBank: AAD40713.1) derived from Bacteroides fragilis , which is an intestinal bacterium, were used.
  • a pET21a plasmid vector containing a gene encoding each enzyme was transformed into E. coli BL21 (DE3) Star.
  • Each recombinant E. coli was cultured at 37° C. and 250 rpm until OD 0.5, and then enzyme expression was induced at 16° C. and 250 rpm for 18 hours using 0.1 mM IPTG.
  • FIG. 1 illustrates a view for producing various types of fucosyl-oligosaccharides using a GDP-fucose donor and various sugar acceptors through the enzymatic reaction of ⁇ -1,2-fucosyltransferase, in which an experiment for reactivity thereof was conducted using sugar acceptors such as glucose, galactose, cellobiose, lactose, fructose, sucrose, maltose, mannose, xylose, and agarobiose.
  • sugar acceptors such as glucose, galactose, cellobiose, lactose, fructose, sucrose, maltose, mannose, xylose, and agarobiose.
  • Bacteroides fragilis -derived WcfB exhibited high activity for cellobiose, galactose, and glucose
  • E. coli O126-derived WbgL exhibited high activity for lactose and galactose
  • Helicobacter pylori -derived FucT2 exhibited high activity for cellobiose and galactose.
  • a fucosyl-oligosaccharide was produced using a GDP-fucose donor and galactose or glucose as an acceptor through the enzymatic reaction of WbgL, which is ⁇ -1,2-fucosyltransferase.
  • the sugar acceptors used in the enzymatic reaction were glucose, galactose, cellobiose, lactose, fructose, sucrose, maltose, mannose, xylose, and agarobiose.
  • Enzymatic reaction conditions were as follows: 1 mg/mL of an intracellular crude enzyme solution of each recombinant E.
  • coli a 0.2 mM GDP-fucose donor, a 0.5 mM sugar acceptor, and a 20 mM sodium phosphate buffer (pH 6.0) were used to allow an enzymatic reaction at 30° C. for 12 hours.
  • the reaction products were subjected to LC/MS analysis to confirm exact mass values.
  • LC/MS analysis a Thermo Hypercarb porous graphitic carbon LC column (Thermo Fisher Scientific) was used, and a positive ion mode was used.
  • Two mobile phases such as a 25 ⁇ M lithium chloride solution as mobile phase A and a 100% acetonitrile solution as mobile phase B were flowed at a rate of 0.2 mL/min with a gradient of 0% to 80% for 41 minutes. At this time, the temperature of the column was maintained at 70° C.
  • Source-dependent parameters were as follows: nebulizing gas flow, 1.5 L/min; interface voltage, 4.5 kV; detector voltage, 1.65 kV; a curved desolvation line (CDL) temperature, 200° C.; and heat block temperature, 200° C.
  • the MS analysis was performed in the range of 100 m/z to 700 m/z.
  • FIG. 6 is a view for producing FGal using recombinant E. coli , in which to produce a GDP-fucose donor in E. coli cells, ManB, ManC, Gmd, and WcaG, which are enzymes involved in the de novo pathway, were introduced and galactose was supplied as an acceptor.
  • E. coli BL21 (DE3) strain which is unable to metabolize galactose, was used as a host.
  • Helicobacter pylori -derived FucT2 was used as ⁇ -1,2-fucosyltransferase, and glycerol was supplied as a carbon source.
  • the recombinant E. coli was cultured in a LB broth medium containing 2 g/L of galactose and 5 g/L of glycerol at 37° C. for 6 hours, and IPTG was added thereto, followed by culture after the temperature was lowered to 25° C.
  • FIG. 6 illustrates fed-batch fermentation results, in which about 12 g/L of FGal was produced after 90 hours of fermentation, and a maximum of 17.7 g/L of FGal was produced after 120 hours of fermentation.
  • FGal was purified from the culture.
  • G-10 column resin and water were used as mobile phases to perform size-exclusion chromatography, and HPLC analysis was performed to confirm FGal fractions purified with high purity.
  • HPLC analysis a Rezex ROA-Organic Acid H+(8%) column (Phenomenex Inc) was used, and a 0.005N sulfuric acid solution was flowed at a rate of 0.6 mL/min at 50° C.
  • a gene encoding the ⁇ -1,2-fucosidase (NCBI Reference Sequence: WP_017167782.1) derived from Xanthomonas manihotis was introduced into a pETduet vector, and then the vector was transformed into the E. coli BL21 (DE3) strain.
  • E. coli BL21 (DE3) strain.
  • 1 mg/mL of FGal was used as a substrate and 1 mg/mL of an intracellular crude enzyme of recombinant E. coli was used and the enzymatic reaction was performed in a 20 mM Tris-HCl buffer (pH 7.0) at 30° C. for 6 hours.
  • an intracellular crude enzyme of recombinant E. coli containing an empty vector free of a gene encoding the enzyme was used to perform an enzymatic reaction.
  • the ⁇ -1,2-glycosidic bond was verified through the enzymatic reaction of ⁇ -1,2-fucosidase of purified 2FG.
  • strains such as Bifidobacterium longum subsp. infantis ATCC 15697 and Bifidobacterium bifidum DSM 20082 was monitored.
  • cell growth of strains such as E. coli O1:K1:H7 and Salmonella enterica serovar typhimurium was monitored.
  • the medium contained 10 g/L of BactoPeptone, 5 g/L of yeast extract, 2 g/L of K 2 HPO 4 (anhydrous), 5 g/L of Na acetate (anhydrous), 2 g/L of NH 4 citrate tribasic, 0.2 g/L of Mg sulfate heptahydrate, 0.05 g/L of Mn sulfate, 1 mL/L of Tween 80 (polysorbate 80), 0.5 g/L of cysteine, and 3 g/L of purified FGal, and the strains were cultured at 37° C.
  • Bifidobacterium bifidum DSM 20082 first decomposed FGal into fucose and galactose extracellularly, and then metabolized a small amount of galactose, and Bifidobacterium longum subsp. infantis ATCC 15697 decomposed FGal into galactose and fucose through intracellular fucosidase and used both.
  • pathogenic microorganisms were unable to metabolize FGal.
  • fucosyl-oligosaccharides can be used as prebiotic materials in medical, cosmetic, and food fields based on the prebiotic properties thereof.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a preparation method for various novel fucosyl oligosaccharides and a use thereof. More specifically, the present invention allows a preparation of various novel fucosyl oligosaccharides through an enzymatic reaction with α-1,2-fucosyltransferase using a GDP-L-fucose donor and various glucose acceptors and an establishment of probiotic characteristics thereof, and thus has an effect of providing uses as materials for medicines, food, cosmetic products, and the like.

Description

CROSS REFERENCE TO RELATED APPLICATIONS
This application is a National Stage of International Application No. PCT/KR2018/014000 filed Nov. 15, 2018, claiming priority based on Korean Patent Application No. 10-2017-0154840 filed Nov. 20, 2017, the disclosure of which is incorporated herein by reference in its entirety.
BACKGROUND 1. Field of the Invention
The present invention relates to a method of producing various novel fucosyl-oligosaccharides through an enzymatic reaction with α-1,2-fucosyltransferase using a GDP-L-fucose donor and various sugar acceptors, and a use thereof as a prebiotic.
2. Discussion of Related Art
Prebiotics refer to substances that are selectively fermented by beneficial intestinal bacteria to improve intestinal flora and are beneficial to human health. Recently, studies on the correlation between human diseases and intestinal flora have been reported, and intestinal flora is recognized as the second human genome, and thus research in this field is rapidly developing. In particular, as study results have been reported, showing that obesity, diabetes, and immune function are improved according to an increase in the distribution of beneficial intestinal flora, research on intestinal flora is receiving more attention.
Fucosyl-oligosaccharides are one of the main components of breast milk oligosaccharides and have activity of prebiotics selectively fermented by probiotic microorganisms and physiological activity that prevents intestinal settlement of pathogenic microorganisms. In addition to intestinal health-related physiological activity, fucosyl-oligosaccharides are known to enhance memory and are expected to help prevent dementia.
Among fucosyl-oligosaccharides, it is known that fucosylgalactose (FGal), which is a disaccharide, promotes the growth of nerve cells when hippocampal neurons, which are brain neural cells, are treated therewith. This suggests the possibility that FGal can be used as an agent for treating nervous system-related diseases such as Alzheimer's disease or Parkinson's disease.
As population aging rapidly progresses worldwide, the number of patients with neurological diseases such as Alzheimer's disease or Parkinson's disease is rapidly increasing, and accordingly, demand for developing effective therapeutic agents is increasing. For example, the global market for Alzheimer's disease therapeutics is expected to expand to $13.3 billion by 2023, and the market for Parkinson's disease therapeutics is expected to expand to $4.7 billion by 2022. However, to date, drugs for alleviating symptoms have been mainly developed, and thus there is no drug for fundamental treatment such that all demands cannot be met, and accordingly, the potential market is expected to greatly expand. In addition, the expansion of purchasing power in the third world, such as Southeast Asia, due to economic growth is expected to contribute to market growth in the future.
The above-described physiological activities of various fucosyl-oligosaccharides, such as prebiotic activity, memory enhancement, and promotion of the growth of nerve cells are expected to result from the fucose unit, and thus the inventors of the present invention produced various types of fucosyl-oligosaccharides using the enzymatic reaction of α-1,2-fucosyltransferase, which is a key enzyme involved in the fucosylation reaction and verified the characteristics thereof as prebiotics, and thus completed the present invention.
SUMMARY OF THE INVENTION
An object of the present invention is to provide a method of producing various fucosyl-oligosaccharides through the enzymatic reaction of α-1,2-fucosyltransferase with a GDP-L-fucose donor and various sugar acceptors.
Another object of the present invention is to provide a use of fucosyl-oligosaccharides having prebiotic properties.
According to an aspect of the present invention, there is provided a prebiotic pharmaceutical composition including one or more fucosyl-oligosaccharides selected from the group consisting of 2′-fucosylglucose, 2′-fucosylgalactose, 2′-fucosylcellobiose, 2′-fucosylfructose, 2′-fucosylsucrose, 2′-fucosylmaltose, 2′-fucosylmannose, 2′-fucosylxylose, and 2′-fucosylagarobiose.
The present invention also provides a method of improving the intestinal health of a subject, including administering the prebiotic pharmaceutical composition to the subject.
The present invention also provides a prebiotic cosmetic composition including one or more fucosyl-oligosaccharides selected from the group consisting of 2′-fucosylglucose, 2′-fucosylgalactose, 2′-fucosylcellobiose, 2′-fucosylfructose, 2′-fucosylsucrose, 2′-fucosylmaltose, 2′-fucosylmannose, 2′-fucosylxylose, and 2′-fucosylagarobiose.
The present invention also relates to a prebiotic food composition including one or more fucosyl-oligosaccharides selected from the group consisting of 2′-fucosylglucose, 2′-fucosylgalactose, 2′-fucosylcellobiose, 2′-fucosylfructose, 2′-fucosylsucrose, 2′-fucosylmaltose, 2′-fucosylmannose, 2′-fucosylxylose, and 2′-fucosylagarobiose.
The present invention also provides a method of producing a fucosyl-oligosaccharide, including reacting a sugar acceptor and a guanosine 5′-diphospho-β-L-fucose (GDP-L-fucose) donor with α-1,2-fucosyltransferase to produce a fucosyl-oligosaccharide,
wherein the sugar acceptor includes one or more selected from the group consisting of glucose, galactose, cellobiose, lactose, fructose, sucrose, maltose, mannose, xylose, and agarobiose, and
the α-1,2-fucosyltransferase includes any one selected from the amino acid sequences of SEQ ID NOS: 1 to 3.
The present invention also provides a method of producing a fucosyl-oligosaccharide, including: culturing, in the presence of a sugar acceptor and glycerol, recombinant E. coli or yeast into which a vector for expressing ManB, ManC, Gmd, and WcaG involved in the de novo pathway for producing a guanosine 5′-diphospho-β-L-fucose (GDP-L-fucose) donor; and a vector for expressing α-1,2-fucosyltransferase are introduced; and separating and purifying a fucosyl-oligosaccharide from the E. coli culture,
wherein the sugar acceptor includes one or more selected from the group consisting of glucose, galactose, cellobiose, lactose, fructose, sucrose, maltose, mannose, xylose, and agarobiose, and
the α-1,2-fucosyltransferase includes any one selected from the amino acid sequences of SEQ ID NOS: 1 to 3.
The present invention has the effect of providing a method of producing a fucosyl-oligosaccharide using the enzymatic reaction of a GDP-L-fucose donor and various sugar acceptors with α-1,2-fucosyltransferase or by applying the enzymatic reaction to a metabolic engineering technique in recombinant E. coli.
The present invention also provides the effect of fucosyl-oligosaccharides to be used as prebiotic materials in medical, cosmetic, and food fields based on the prebiotic properties thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a view illustrating the production of various types of fucosyl-oligosaccharides using a GDP-fucose donor and various sugar acceptors through the enzymatic reaction of α-1,2-fucosyltransferase.
FIG. 2 illustrates test results showing the reactivity between α-1,2-fucosyltransferase and various sugar acceptors.
FIGS. 3 to 5 illustrate LC/MS analysis results of fucosyl-oligosaccharides produced through the enzymatic reaction with α-1,2-fucosyltransferase using a GDP-L-fucose donor and sugar acceptors such as glucose, galactose, cellobiose, lactose, fructose, sucrose, maltose, mannose, xylose, and agarobiose.
FIG. 6 illustrates a view for producing 2-fucosylgalactose using recombinant E. coli (A), and batch fermentation results (B) and fed-batch fermentation results (C) of recombinant E. coli.
FIG. 7 illustrates 2-fucosylgalactose (B) separated and purified by size-exclusion chromatography using a G-10 column in a fermentation broth of recombinant E. coli (A), results of the enzymatic reaction of α-1,2-fucosyltransferase using 2-fucosylgalactose as a substrate to confirm the α-1,2-glycosidic bond of 2-fucosylgalactose (D), and results of the enzymatic reaction of α-1,2-fucosidase of a crude enzyme solution of recombinant E. coli including, as a control, an empty vector free of a gene encoding the enzyme (C).
FIG. 8 illustrates the results of confirming the prebiotic activity of 2-fucosylgalactose in a strain belonging to the genus Bifidobacterium.
FIG. 9 illustrates the results of confirming the metabolism of 2-fucosylgalactose in pathogenic microorganisms.
 DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS
The inventors of the present invention first produced fucosylgalactose (FGal) (U.S. Pat. No. 7,858,578), which has been produced only by chemical synthesis until now, through an enzymatic reaction and microbial fermentation. In addition, the inventors first proved that FGal is a prebiotic fermented by Bifidobacter, which is a probiotic microorganism. In particular, among various sugar acceptors, agarobiose, which is a disaccharide basic structure constituting agarose, a major carbohydrate of red algae, was used to first produce 2-fucosylagarobiose. Agarobiose is known as a bioactive substance with antioxidant, antimicrobial, anti-inflammatory, and anticancer effects, and 2-fucosylagarobiose produced through the fucosylation reaction is a new material and is also expected to be a material with various physiological activities.
Therefore, the present invention relates to a prebiotic pharmaceutical composition including one or more fucosyl-oligosaccharides selected from the group consisting of 2′-fucosylglucose, 2′-fucosylgalactose, 2′-fucosylcellobiose, 2′-fucosylfructose, 2′-fucosylsucrose, 2′-fucosylmaltose, 2′-fucosylmannose, 2′-fucosylxylose, and 2′-fucosylagarobiose.
The fucosyl-oligosaccharide(s) are prebiotics that promote the proliferation of beneficial intestinal bacteria, inhibit the growth of harmful intestinal bacteria, and are not metabolized by pathogenic microorganisms. In addition, by binding to the adhesion sites or receptor sites of Salmonella, Helicobacter, Pathogenic E. coli, Norovirus, and the like, the fucosyl-oligosaccharide(s) may also prevent pathogenic bacteria and viruses from infecting the human body and proliferating. Thereamong, 2-fucosylgalactose may be used as a therapeutic agent for neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease through promotion of the growth of nerve cells, and 2-fucosylagarobiose can also be used as antioxidant, antibacterial, anti-inflammatory, and anticancer agents due to properties of agarobiose itself, such as antioxidant, antibacterial, anti-inflammatory, and anticancer properties.
According to one embodiment of the present invention, Bifidobacterium longum subsp. infantis ATCC 15697 decomposes 2-fucosylgalactose into galactose and fucose through intracellular fucosidase and uses both, and Bifidobacterium bifidum DSM 20082 extracellularly decomposes 2-fucosylgalactose into galactose and fucose, and then uses only galactose. In addition, it can be seen that E. coli, which causes urinary tract infections, neonatal meningitis, and septicemia, and Salmonella enterica serovar typhimurium, which causes diarrhea and bacteremia, are unable to metabolize 2-fucosylgalactose and are prebiotics selectively fermented only by probiotic microorganisms.
The fucosyl-oligosaccharide(s) may be produced by reacting a sugar acceptor and a guanosine 5′-diphospho-β-L-fucose (GDP-L-fucose) donor with α-1,2-fucosyltransferase. Alternatively, recombinant E. coli or yeast into which a vector for expressing ManB, ManC, Gmd, and WcaG involved in the de novo pathway for producing GDP-L-fucose; and a vector for expressing α-1,2-fucosyltransferase are introduced may be cultured in the presence of a sugar acceptor and glycerol, respectively, and fucosyl-oligosaccharide(s) may be obtained from the culture by separation and purification.
As used herein, the term “beneficial intestinal bacteria” has the same meaning as “probiotics” and refers to strains that have a beneficial effect on the intestinal environment when ingested and reaching the intestine, and means bacteria that survive in stomach acid and bile acid to reach the small intestine and consequently, proliferate and settle in the intestine, have a beneficial effect in the intestinal tract, and satisfy conditions such as no toxicity and non-pathogenicity. For example, the beneficial intestinal bacteria include bacteria belonging to the genus Lactobacillus, the genus Lactococcus, the genus Enterococcus, the genus Streptococcus, and the genus Bifidobacterium. In particular, the beneficial intestinal bacteria are strains belonging to the genus Bifidobacterium, the genus Lactobacillus, or the genus Streptococcus, more particularly strains belonging to the genus Bifidobacterium or the genus Streptococcus. Still more particularly, the strain belonging to the genus Bifidobacterium according to the present invention includes Bifidobacterium longum subsp. infantis ATCC 15697, Bifidobacterium bifidum DSM 20082, or Bifidobacterium kashiwanohence DSM 21854. The strain belonging to the genus Lactobacillus includes Lactobacillus reuteri, and the strain belonging to the genus Streptococcus includes Streptococcus thermophilus.
As used herein, the term “harmful intestinal bacteria” refers to strains that have an adverse effect on the intestinal environment when ingested and reaching the intestine. For example, the harmful intestinal bacteria include strains belonging to the genus Pseudomonas-aeruginosa, the genus Vibrio, the genus Staphylococcus, the genus Clostridium perfringens, the genus Eubacterium, and the genus Bacteroides, and sulfate reducers. Particularly, the harmful intestinal bacteria are strains belonging to the genus Clostridium perfringens, the genus Eubacterium, or the genus Bacteroides. More particularly, the strain belonging to the genus Clostridium perfringens includes Clostridium difficile or Clostridium perfringens. The strain belonging to the genus Eubacterium includes Eubacterium limosum, and the strain belonging to the genus Bacteroides includes Bacteroides fragilis.
The prebiotic pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier.
The pharmaceutically acceptable carrier includes carriers and vehicles commonly used in the medical field, and particularly, includes ion exchange resins, alumina, aluminum stearate, lecithin, serum proteins (e.g., human serum albumin), buffer substances (e.g., various phosphates, glycine, sorbic acid, potassium sorbate, and partial glyceride mixtures of saturated vegetable fatty acids), water, salts or electrolytes (e.g., protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, and zinc salts), colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substrates, polyethylene glycol, sodium carboxymethylcellulose, polyarylates, wax, polyethylene glycol, or lanolin, but the present invention is not limited thereto.
In addition, the prebiotic pharmaceutical composition of the present invention may further include, in addition to the above-described ingredients, a lubricant, a wetting agent, an emulsifying agent, a suspension agent, a preservative, or the like.
In one embodiment, the prebiotic pharmaceutical composition of the present invention may be formulated and used in the form of various preparations suitable for oral administration or parenteral administration.
Non-limiting examples of the preparations for oral administration include troches, lozenges, tablets, aqueous suspensions, oily suspensions, prepared powders, emulsions, hard capsules, soft capsules, syrups, and elixirs.
To formulate the prebiotic pharmaceutical composition of the present invention for oral administration, a binder such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose, gelatin, or the like; an excipient such as dicalcium phosphate or the like; a disintegrant such as corn starch, sweet potato starch, or the like; a lubricant such as magnesium stearate, calcium stearate, sodium stearyl fumarate, polyethylene glycol wax, or the like; or the like may be used, and a sweetener, a fragrance, syrup, or the like may also be used.
Furthermore, in the case of capsules, a liquid carrier such as a fatty oil, and the like may be further used in addition to the aforementioned materials.
Non-limiting examples of the preparations for parenteral administration may include injections, suppositories, respiratory inhalation powders, spray aerosols, oral sprays, mouthwashes, toothpastes, ointments, powders for application, oils, and creams.
To formulate the prebiotic pharmaceutical composition of the present invention to be used for parenteral administration, sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, agents for external application, or the like may be used, and as the non-aqueous solvents and the suspensions, propylene glycol, polyethylene glycol, a vegetable oil such as olive oil, an injectable ester such as ethyl oleate, or the like may be used.
In addition, more particularly, when the prebiotic pharmaceutical composition of the present invention is formulated into an injection, the prebiotic pharmaceutical composition of the present invention is mixed with a stabilizer or a buffer in water to prepare a solution or a suspension, followed by preparation into an ampoule or vial unit dosage form. In addition, when the pharmaceutical composition of the present invention is formulated into an aerosol, a propellant or the like for dispersing a water-dispersed concentrate or wet powder may be blended with an additive.
In addition, when the prebiotic pharmaceutical composition of the present invention is formulated into an ointment, a cream, or the like, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, a cellulose derivative, polyethylene glycol, silicon, bentonite, silica, talc, zinc oxide, or the like may be used as a carrier.
A pharmaceutically effective amount and effective dosage level of the prebiotic pharmaceutical composition of the present invention may vary depending on formulation methods, administration methods, administration time, and/or administration route of the composition, and may vary depending on various factors including the type and degree of reaction to be achieved via administration of the prebiotic pharmaceutical composition of the present invention, the type, age, and body weight of an individual to which the composition is administered, general health condition, the symptoms or severity of disease, gender, diet, excretion, drugs used simultaneously or at different times in the corresponding individual, components of other compositions, and the like, and similar factors well known in the medical field, and one of ordinary skill in the art can determine and prescribe an effective dose for targeted treatment. The prebiotic pharmaceutical composition of the present invention may be administered once a day or in multiple doses. Thus, the effective dose is not intended to limit the scope of the present invention in any way.
The administration route and administration method of the prebiotic pharmaceutical composition of the present invention may be independent from each other, the administration method is not particularly limited, and the administration route and the administration method may be an arbitrary administration route and administration route as long as they enable the prebiotic pharmaceutical composition to reach the corresponding site. The prebiotic pharmaceutical composition may be administered orally or parenterally.
The parenteral administration may be, for example, intravenous administration, intraperitoneal administration, intramuscular administration, transdermal administration, subcutaneous administration, or the like, and the prebiotic pharmaceutical composition may be applied or sprayed on a diseased site, or inhaled, but the present invention is not limited thereto.
The prebiotic pharmaceutical composition of the present invention may preferably be administered orally or by injection.
The present invention also provides a method of improving the intestinal health of a subject, including administering the prebiotic pharmaceutical composition to the subject.
The method of improving the intestinal health according to the present invention includes treating heartburn, indigestion, abdominal bloating, diarrhea, constipation, gas, or the like.
As used herein, the term “subject” means all animals including mammals including mice, livestock, humans, and the like.
In the method of improving the intestinal health according to the present invention, detailed descriptions of the dosage, administration route, administration method, and the like of the prebiotic pharmaceutical composition are the same as those described above with respect to the pharmaceutical composition.
The present invention also provides a prebiotic cosmetic composition including one or more fucosyl-oligosaccharides selected from the group consisting of 2′-fucosylglucose, 2′-fucosylgalactose, 2′-fucosylcellobiose, 2′-fucosylfructose, 2′-fucosylsucrose, 2′-fucosylmaltose, 2′-fucosylmannose, 2′-fucosylxylose, and 2′-fucosylagarobiose.
Oligosaccharides including fucose may exhibit functionality that thickens the skin epidermal layer to alleviate wrinkles. Therefore, in consideration of skin permeability and absorption rate, fucosyl-oligosaccharides may exhibit excellent anti-wrinkle activity. Among the fucosyl-oligosaccharides, 2′-fucosylagarobiose can be effectively used to inhibit or treat atopy, acne, dandruff, and the like through the antioxidant and antibacterial activities of agarobiose itself.
The cosmetic composition of the present invention includes: water-soluble vitamins such as vitamin B1, vitamin B2, vitamin B6, pyridoxine, pyridoxine hydrochloride, vitamin B12, pantothenic acid, nicotinic acid, nicotinic acid amide, folic acid, vitamin C, vitamin H, and the like; oil-soluble vitamins such as vitamin A, carotene, vitamin D2, vitamin D3, vitamin E (d1-alpha tocopherol, d-alpha tocopherol, d-alpha tocopherol), and the like; polymer peptides such as collagen, hydrolyzed collagen, gelatin, elastin, hydrolyzed elastin, keratin, and the like; polymeric polysaccharides such as hydroxyethyl cellulose, xanthan gum, sodium hyaluronate, chondroitin sulfate or salts thereof (sodium salts and the like), and the like; sphingolipids such as ceramide, phytosphingosine, sphingosaccharide lipid, and the like; or seaweed extracts such as a brown algae extract, a red algae extract, a green algae extract, and the like.
The cosmetic composition of the present invention may include, in addition to the above essential ingredients, other ingredients mixed in general cosmetics as necessary. Other mixed ingredients that may be added may include oil and fat ingredients, a moisturizing agent, an emollient agent, a surfactant, organic and inorganic pigments, organic powders, an ultraviolet absorbent, a preservative, a bactericide, an antioxidant, a plant extract, a pH adjusting agent, alcohols, dyes, pigments, a blood circulation promoter, a cooling agent, an antiperspirant, purified water, and the like. Oil and fat ingredients may include ester-based oil and fat, hydrocarbon-based oil and fat, silicone-based oil and fat, fluorine-based oil and fat, animal oil and fat, vegetable oil and fat, and the like.
In addition, other mixed ingredients that may be added are not limited to the above examples, and may be mixed within a range that does not adversely affect the objects and effects of the present invention.
The cosmetic composition of the present invention may be in the form of a solution, an emulsion, a viscous mixture, or the like.
The ingredients included in the cosmetic composition of the present invention may include ingredients commonly used in cosmetic compositions as active ingredients, and include, for example, general adjuvants and carriers such as a stabilizer, a solubilizer, vitamins, a pigment, and a flavor.
The cosmetic composition of the present invention may be prepared into any form generally prepared in the art, and examples thereof include a skin lotion, a skin softener, a skin toner, a milk lotion, an astringent, a lotion, a moisturizing lotion, a nourishing lotion, a massage cream, a nourishing cream, a moisturizing cream, a hand cream, a foundation, an essence, a nourishing essence, a pack, a soap, a cleansing foam, a cleansing lotion, a cleansing cream, a hair lotion, a hair tonic, a hair essence, a hair shampoo, a hair rinse, a hair treatment, a body lotion, and a body cleanser.
The present invention also provides a prebiotic food composition including one or more fucosyl-oligosaccharides selected from the group consisting of 2′-fucosylglucose, 2′-fucosylgalactose, 2′-fucosylcellobiose, 2′-fucosylfructose, 2′-fucosylsucrose, 2′-fucosylmaltose, 2′-fucosylmannose, 2′-fucosylxylose, and 2′-fucosylagarobiose.
The food composition of the present invention may be used as a health functional food, a food additive, or a dietary supplement.
When used as a food additive, the fucosyl-oligosaccharide(s) may be appropriately used according to a general method such as being added directly or mixed in combination with other foods or food ingredients.
In addition, the amount of fucosyl-oligosaccharide(s) to be mixed may be appropriately changed according to the purpose of use (prevention, health or therapeutic treatment), and ranges from preferably 0.01 wt % to 95 wt %, more preferably 0.1 wt % to 80 wt %, with respect to a total weight of the food composition. When the amount is less than 0.01 wt %, dose efficiency may be lowered, and when the amount is greater than 95 wt %, there may be difficulties in formulation.
Specifically, when prepared into a food or a beverage, the fucosyl-oligosaccharide(s) of the present invention are added in an amount of 15 wt % or less, preferably 10 wt % or less, with respect to a total weight of raw materials. However, in the case of long-term ingestion for health and hygienic purposes or for health control purposes, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may also be used in an amount above the above range.
The type of the food is not particularly limited, but examples of foods to which the fucosyl-oligosaccharide(s) of the present invention may be added include meats, sausages, bread, chocolates, candies, snacks, confectionaries, pizzas, instant noodles, other noodles, gums, dairy products including ice creams, various kinds of soup, beverages, teas, drinks, alcoholic drinks, vitamin complexes, and the like, and all health foods in the ordinary sense are included.
When the food composition of the present invention is prepared as a beverage, the food composition may include additional ingredients such as various flavor enhancers or natural carbohydrates like general beverages. As the natural carbohydrates, monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; natural sweeteners such as dextrin and cyclodextrin; and synthetic sweeteners such as saccharin and aspartame may be used. The natural carbohydrate is included in an amount of 0.01 wt % to 10 wt %, preferably 0.01 wt % to 0.1 wt %, with respect to the total weight of the food composition of the present invention.
The food composition of the present invention may include various nutritional supplements, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, a protective colloid thickener, a pH adjuster, a stabilizer, a preservative, glycerin, alcohols, a carbonating agent used in carbonated beverages, and the like, and may include flesh for the preparation of natural fruit juice, fruit juice beverages, and vegetable beverages, but the present invention is not limited thereto. These ingredients may be used alone or a combination thereof may be used. The proportion of these additives is not particularly limited, but may range from 0.01 wt % to 0.1 wt % with respect to the total weight of the food composition of the present invention.
In the case of long-term ingestion for health and hygienic purposes or for health control purposes, the food composition of the present invention may be ingested for a long period of time since there is no problem in terms of safety.
The present invention also provides a method of producing a fucosyl-oligosaccharide, including reacting a sugar acceptor and a guanosine 5′-diphospho-β-L-fucose (GDP-L-fucose) donor with α-1,2-fucosyltransferase to produce a fucosyl-oligosaccharide,
wherein the sugar acceptor includes one or more selected from the group consisting of glucose, galactose, cellobiose, lactose, fructose, sucrose, maltose, mannose, xylose, and agarobiose, and
the α-1,2-fucosyltransferase includes any one selected from the amino acid sequences of SEQ ID NOS: 1 to 3.
As a conventional method for producing fucosyl-oligosaccharides, chemical synthesis of 2-fucosylgalactose is known, but this method has a complicated synthesis process and uses organic solvents such as pyridine, acetic acid, dichloromethane, and toluene, and even after many processes, synthesis was possible only in a derivatized form, not 2-fucosylgalactose (Kalovidouris S A et al. J Ame Chem Soc 127: 1340-1341 (2005)).
However, in the method of producing a fucosyl-oligosaccharide according to the present invention, by reacting a sugar acceptor and a GDP-L-fucose donor with α-1,2-fucosyltransferase, a fucosyl-oligosaccharide, not a derivatized form, can be produced. In addition, it is possible to produce various types of fucosyl-oligosaccharides using various sugar acceptors (see FIG. 1).
The sugar acceptor may be selected from the group consisting of glucose, galactose, cellobiose, lactose, fructose, sucrose, maltose, mannose, xylose, and agarobiose.
The α-1,2-fucosyltransferase may be derived from Helicobacter pylori, Bacteroides fragilis, E. coli O126, or the like, and particularly, may include any one selected from the amino acid sequences of SEQ ID NOS: 1 to 3.
According to one embodiment of the present invention, the α-1,2-fucosyltransferase showed a difference in reactivity according to the type of sugar acceptor. For example, Bacteroides fragilis-derived WcfB exhibited high activity for cellobiose, galactose, and glucose, E. coli O126-derived WbgL exhibited high activity for lactose and galactose, and Helicobacter pylori-derived FucT2 exhibited high activity for cellobiose and galactose.
The enzymatic reaction of the sugar acceptor and the GDP-L-fucose donor with α-1,2-fucosyltransferase may be performed at 20° C. to 40° C. for 3 hours to 24 hours, more particularly at 25° C. to 35° C. for 6 hours to 12 hours.
A fucosyl-oligosaccharide produced by the method of producing a fucosyl-oligosaccharide according to the present invention may be 2′-fucosylglucose, 2′-fucosylgalactose, 2′-fucosylcellobiose, 2′-fucosyllactose, 2′-fucosylfructose, 2′-fucosylsucrose, 2′-fucosylmaltose, 2′-fucosylmannose, 2′-fucosylxylose, or 2′-fucosylagarobiose.
The present invention also provides a method of producing a fucosyl-oligosaccharide, including: culturing, in the presence of a sugar acceptor and glycerol, recombinant E. coli or yeast into which a vector for expressing ManB, ManC, Gmd, and WcaG involved in the de novo pathway for producing a guanosine 5′-diphospho-β-L-fucose (GDP-L-fucose) donor; and a vector for expressing α-1,2-fucosyltransferase are introduced; and separating and purifying a fucosyl-oligosaccharide from the E. coli culture,
wherein the sugar acceptor includes one or more selected from the group consisting of glucose, galactose, cellobiose, lactose, fructose, sucrose, maltose, mannose, xylose, and agarobiose, and
the α-1,2-fucosyltransferase includes any one selected from the amino acid sequences of SEQ ID NOS: 1 to 3.
According to a method of producing 2-fucosyllactose, which is a fucosyl-oligosaccharide, through fermentation by employing a conventional microorganism metabolic engineering technique, 2-fucosyllactose is produced from lactose using Helicobacter-derived fucosyltransferase, but it is disadvantageous in that it is not possible to produce various fucosyl-oligosaccharides.
In contrast, according to the method of producing a fucosyl-oligosaccharide according to the present invention, various types of fucosyl-oligosaccharides may be produced through microbial fermentation by employing a microorganism metabolic engineering technique, and to this end, E. coli or yeast in which the metabolic pathway of a material used as a sugar acceptor is deleted is used as a host, the de novo pathway is introduced into the host to produce GDP-1-fucose as a donor, a sugar substance is supplied as an acceptor, glycerol is used as a carbon source, and α-1,2-fucosyltransferase is introduced, thereby producing fucosyl-oligosaccharides through fermentation. Therefore, the method of the present invention may include:
constructing a vector for expressing ManB, ManC, Gmd, and WcaG involved in the de novo pathway for producing, as a donor, guanosine 5′-diphospho-β-L-fucose (GDP-L-fucose) in E. coli, and a vector for expressing α-1,2-fucosyltransferase;
introducing the vectors into E. coli or a yeast in which the metabolic pathway of a material used as a sugar acceptor is deleted to transform the E. coli or yeast;
culturing the transformed E. coli or yeast using glycerol as a carbon source in the presence of a sugar acceptor; and
separating and purifying a fucosyl-oligosaccharide from the culture.
The de novo pathway for producing GDP-L-fucose is a pathway in which, by using fructose 6P as a starting material and mannose-6-phosphate isomerase (ManM), phosphomannomutase (ManB), mannose-1-phosphate guanosyltransferase (ManC), GDP-mannose-4,6-dehydratase (Gmd), and GDP-L-fucose synthase (WcaG), intermediate products such as mannose 6P, mannose 1P, GDP-D-mannose, and GDP-4-keto-6-deoxymannose are sequentially produced, and finally, GDP-L-fucose is produced.
The culture of the transformed E. coli may include fed-batch culture.
The fed-batch culture may be performed at 25° C. to 37° C. for 2 hours to 60 hours, and isopropyl β-D-1-thiogalactopyranoside (IPTG) may be added and the fed-batch culture may be performed at 20° C. to 30° C. for 60 hours to 150 hours.
Hereinafter, the present invention will be described in further detail with reference to the following examples, but these examples are not intended to limit the scope of the present invention.
<Example 1> Synthesis of Fucosyl-Oligosaccharides
To produce various fucosyl-oligosaccharides, the enzymatic reaction of α-1,2-fucosyltransferase under conditions of a GDP-fucose donor and various sugar acceptors was performed (see FIG. 1).
As the α-1,2-fucosyltransferases, E. coli-derived WbgL (GenBank: ABE98421.1), Helicobacter pylori-derived FucT2 (GenBank: AAC99764.1), and WcfB (GenBank: AAD40713.1) derived from Bacteroides fragilis, which is an intestinal bacterium, were used. A pET21a plasmid vector containing a gene encoding each enzyme was transformed into E. coli BL21 (DE3) Star. Each recombinant E. coli was cultured at 37° C. and 250 rpm until OD 0.5, and then enzyme expression was induced at 16° C. and 250 rpm for 18 hours using 0.1 mM IPTG.
FIG. 1 illustrates a view for producing various types of fucosyl-oligosaccharides using a GDP-fucose donor and various sugar acceptors through the enzymatic reaction of α-1,2-fucosyltransferase, in which an experiment for reactivity thereof was conducted using sugar acceptors such as glucose, galactose, cellobiose, lactose, fructose, sucrose, maltose, mannose, xylose, and agarobiose.
To produce agarobiose, acid hydrolysis of agarose was performed. 10% (w/w) agarose was subjected to an acid hydrolysis reaction using 2% phosphoric acid at 90° C. for 3 hours. After the acid hydrolysis, calcium hydroxide was added to the reaction solution to neutralize and remove phosphoric acid.
An experiment for enzymatic reactivity between the α-1,2-fucosyltransferases and various sugar acceptors was conducted as follows. A 2 mM GDP-fucose donor, 5 mM of each sugar acceptor, 1 mM 1,4-dithiothreitol (DTT), 50 mM Tris-HCl (pH 7.0), and 5 mg/mL of an intracellular crude enzyme solution of E. coli expressing WbgL, FucT2, or WcfB were allowed to react at 30° C. and 600 rpm for 12 hours.
As shown in FIG. 2, Bacteroides fragilis-derived WcfB exhibited high activity for cellobiose, galactose, and glucose, E. coli O126-derived WbgL exhibited high activity for lactose and galactose, and Helicobacter pylori-derived FucT2 exhibited high activity for cellobiose and galactose.
<Example 2> Enzymatic Reaction of α-1,2-Fucosyltransferase for Various Sugar Acceptors
A fucosyl-oligosaccharide was produced using a GDP-fucose donor and galactose or glucose as an acceptor through the enzymatic reaction of WbgL, which is α-1,2-fucosyltransferase. The sugar acceptors used in the enzymatic reaction were glucose, galactose, cellobiose, lactose, fructose, sucrose, maltose, mannose, xylose, and agarobiose. Enzymatic reaction conditions were as follows: 1 mg/mL of an intracellular crude enzyme solution of each recombinant E. coli, a 0.2 mM GDP-fucose donor, a 0.5 mM sugar acceptor, and a 20 mM sodium phosphate buffer (pH 6.0) were used to allow an enzymatic reaction at 30° C. for 12 hours. The reaction products were subjected to LC/MS analysis to confirm exact mass values. In the LC/MS analysis, a Thermo Hypercarb porous graphitic carbon LC column (Thermo Fisher Scientific) was used, and a positive ion mode was used. Two mobile phases such as a 25 μM lithium chloride solution as mobile phase A and a 100% acetonitrile solution as mobile phase B were flowed at a rate of 0.2 mL/min with a gradient of 0% to 80% for 41 minutes. At this time, the temperature of the column was maintained at 70° C. Source-dependent parameters were as follows: nebulizing gas flow, 1.5 L/min; interface voltage, 4.5 kV; detector voltage, 1.65 kV; a curved desolvation line (CDL) temperature, 200° C.; and heat block temperature, 200° C. The MS analysis was performed in the range of 100 m/z to 700 m/z.
As illustrated in FIGS. 3 to 5, it was confirmed that, for each sugar acceptor, 2′-fucosylglucose, 2′-fucosylgalactose, 2′-fucosylcellobiose, 2′-fucosyllactose, 2′-fucosylfructose, 2′-fucosylsucrose, 2′-fucosylmaltose, 2′-fucosylmannose, 2′-fucosylxylose, or 2′-fucosylagarobiose were produced.
<Example 3> Production of Fucosylgalactose Using Metabolic Engineering Technique
To produce FGal, which is a bioactive substance from recombinant E. coli, metabolic engineering was employed and then fermentation was performed. A of FIG. 6 is a view for producing FGal using recombinant E. coli, in which to produce a GDP-fucose donor in E. coli cells, ManB, ManC, Gmd, and WcaG, which are enzymes involved in the de novo pathway, were introduced and galactose was supplied as an acceptor. To use galactose as an acceptor, an E. coli BL21 (DE3) strain, which is unable to metabolize galactose, was used as a host. Helicobacter pylori-derived FucT2 was used as α-1,2-fucosyltransferase, and glycerol was supplied as a carbon source. The recombinant E. coli was cultured in a LB broth medium containing 2 g/L of galactose and 5 g/L of glycerol at 37° C. for 6 hours, and IPTG was added thereto, followed by culture after the temperature was lowered to 25° C.
As illustrated in B of FIG. 6, 1.7 g/L of FGal was produced after batch fermentation for 90 hours.
C of FIG. 6 illustrates fed-batch fermentation results, in which about 12 g/L of FGal was produced after 90 hours of fermentation, and a maximum of 17.7 g/L of FGal was produced after 120 hours of fermentation.
<Example 4> Verification of Structure of 2-Fucosylgalactose Produced Through Metabolic Engineering Technique
To confirm the structure of FGal produced via recombinant E. coli, FGal was purified from the culture. At this time, G-10 column resin and water were used as mobile phases to perform size-exclusion chromatography, and HPLC analysis was performed to confirm FGal fractions purified with high purity. In the HPLC analysis, a Rezex ROA-Organic Acid H+(8%) column (Phenomenex Inc) was used, and a 0.005N sulfuric acid solution was flowed at a rate of 0.6 mL/min at 50° C.
To confirm the α-1,2-glycosidic bond of the purified FGal, FGal as a substrate was subjected to the enzymatic reaction of α-1,2-fucosidase derived from Xanthomonas manihotis.
To this end, a gene encoding the α-1,2-fucosidase (NCBI Reference Sequence: WP_017167782.1) derived from Xanthomonas manihotis was introduced into a pETduet vector, and then the vector was transformed into the E. coli BL21 (DE3) strain. During the enzymatic reaction, 1 mg/mL of FGal was used as a substrate and 1 mg/mL of an intracellular crude enzyme of recombinant E. coli was used and the enzymatic reaction was performed in a 20 mM Tris-HCl buffer (pH 7.0) at 30° C. for 6 hours. At this time, as a control, an intracellular crude enzyme of recombinant E. coli containing an empty vector free of a gene encoding the enzyme was used to perform an enzymatic reaction.
As illustrated in FIG. 7, the α-1,2-glycosidic bond was verified through the enzymatic reaction of α-1,2-fucosidase of purified 2FG.
<Example 5> Verification of Prebiotic Properties of 2-Fucosylgalactose
To verify the prebiotic effect of FGal, the cell growth of strains such as Bifidobacterium longum subsp. infantis ATCC 15697 and Bifidobacterium bifidum DSM 20082 was monitored. In addition, to conduct a test for the capabilities of pathogenic microorganisms to ferment FGal, the cell growth of strains such as E. coli O1:K1:H7 and Salmonella enterica serovar typhimurium was monitored. At this time, the medium contained 10 g/L of BactoPeptone, 5 g/L of yeast extract, 2 g/L of K2HPO4 (anhydrous), 5 g/L of Na acetate (anhydrous), 2 g/L of NH4 citrate tribasic, 0.2 g/L of Mg sulfate heptahydrate, 0.05 g/L of Mn sulfate, 1 mL/L of Tween 80 (polysorbate 80), 0.5 g/L of cysteine, and 3 g/L of purified FGal, and the strains were cultured at 37° C.
As illustrated in FIG. 8, it was confirmed that Bifidobacterium bifidum DSM 20082 first decomposed FGal into fucose and galactose extracellularly, and then metabolized a small amount of galactose, and Bifidobacterium longum subsp. infantis ATCC 15697 decomposed FGal into galactose and fucose through intracellular fucosidase and used both.
As illustrated in FIG. 9, pathogenic microorganisms were unable to metabolize FGal.
According to the present invention, fucosyl-oligosaccharides can be used as prebiotic materials in medical, cosmetic, and food fields based on the prebiotic properties thereof.

Claims (5)

What is claimed is:
1. A method of producing a fucosyl-oligosaccharide comprising
reacting a sugar acceptor and a guanosine 5′-diphospho-p-L-fucose (GDP-L-fucose) donor with α-1,2-fucosyltransferase to produce a fucosyl-oligosaccharide,
wherein the sugar acceptor is selected from the group consisting of glucose, galactose, cellobiose, lactose, fructose, sucrose, maltose, mannose, xylose, and agarobiose,
the α-1,2-fucosyltransferase is selected from a sequence comprising the amino acid sequence of SEQ ID NO: 2, and
the fucosyl-oligosaccharide is selected from the group consisting of 2′-fucosylglucose, 2′-fucosylgalactose, 2′-fucosylcellobiose, 2′-fucosylfructose, 2′-fucosylsucrose, 2′-fucosylmaltose, 2′-fucosylmannose, 2′-fucosylxylose, and 2′-fucosylagarobiose, wherein the reacting is performed in the presence of a vector for expressing a phosphomannomutase (ManB), a mannose 1-phosphate guanylytransferase (ManC), a GDP-D-mannose-4,6-dehydratse (Gmd) and a GDP-4-keto-6-deoxymannose 3,5-epimerase 4-reductase (WcaG) for producing the GDP-L-fucose.
2. The method of claim 1, wherein the reacting is performed at 20° C. to 40° C. for 3 hours to 24 hours.
3. A method of producing a fucosyl-oligosaccharide comprising
culturing, in the presence of a sugar acceptor and glycerol, recombinant E. coli or yeast into which a vector for expressing ManB, ManC, Gmd, and WcaG involved in the de novo pathway for producing a guanosine 5′-diphospho-β-L-fucose (GDP-L-fucose) donor, and a vector for expressing α-1,2-fucosyltransferase are introduced, and
separating and purifying the fucosyl-oligosaccharide from the E. coli or yeast culture,
wherein the sugar acceptor is selected from the group consisting of glucose, galactose, cellobiose, lactose, fructose, sucrose, maltose, mannose, xylose, and agarobiose, and
the α-1,2-fucosyltransferase is selected from a sequence comprising the amino acid sequence of SEQ ID NO: 2.
4. The method of claim 3, wherein the culturing is fed-batch culture.
5. The method of claim 4, wherein the fed-batch culture is performed at 25° C. to 37° C. for 2 hours to 60 hours, and isopropyl β-D-1-thiogalactopyranoside (IPTG) is added thereto, followed by further fed-batch culture at 20° C. to 30° C. for 60 hours to 150 hours.
US16/765,359 2017-11-20 2018-11-15 Preparation method for various novel fucosyl oligosaccharides and use thereof Active 2038-12-08 US11504386B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020170154840A KR101953375B1 (en) 2017-11-20 2017-11-20 Method for producing various novel fucosylated oligosaccharides and use thereof
KR10-2017-0154840 2017-11-20
PCT/KR2018/014000 WO2019098706A2 (en) 2017-11-20 2018-11-15 Preparation method for various novel fucosyl oligosaccharides and use thereof

Publications (2)

Publication Number Publication Date
US20200338101A1 US20200338101A1 (en) 2020-10-29
US11504386B2 true US11504386B2 (en) 2022-11-22

Family

ID=65584492

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/765,359 Active 2038-12-08 US11504386B2 (en) 2017-11-20 2018-11-15 Preparation method for various novel fucosyl oligosaccharides and use thereof

Country Status (4)

Country Link
US (1) US11504386B2 (en)
KR (1) KR101953375B1 (en)
CN (1) CN111629732A (en)
WO (1) WO2019098706A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022008163A1 (en) * 2020-07-10 2022-01-13 Unilever Ip Holdings B.V. Use of trehalose as prebiotic for inhibiting ailment inducing microorganisms
CN116286562B (en) * 2021-12-10 2024-09-10 虹摹生物科技(上海)有限公司 Genetically engineered bacterium and preparation method and application thereof
KR102686044B1 (en) * 2022-04-28 2024-07-19 주식회사 에이치이엠파마 A novel strain of bifidobacterium bifidum hem972, and composition for improving gut environment comprising the strain or its culture fluid
US12133858B2 (en) 2022-12-16 2024-11-05 Advanced Protein Technologies Corp. Composition for promoting hair growth and improving, preventing, or treating hair loss containing 2′-fucosyllactose as an active ingredient
KR102567042B1 (en) * 2022-12-16 2023-08-16 (주)에이피테크놀로지 Composition for promoting hair growth and improving, preventing or treating hair loss comprising 2'-fucosyllactose as an active ingredient
CN116211729A (en) * 2023-03-03 2023-06-06 苏州一兮生物技术有限公司 A composition capable of improving skin microecology and its application
WO2025087087A1 (en) * 2023-10-23 2025-05-01 山东恒鲁生物科技有限公司 Fucosyltransferase polypeptide and use thereof
WO2025211291A1 (en) * 2024-04-01 2025-10-09 キリンホールディングス株式会社 Composition containing 2'-fucosyl galactose and method for producing same

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040048331A1 (en) * 1998-11-04 2004-03-11 Governors Of The University Of Alberta, A Canada Corporation Alpha 1,2 fucosyltransferase
US20040058418A1 (en) * 2000-04-11 2004-03-25 Tetsuo Endo Alpha 1,2-fucosyltransferase and process for producing fucose-containing complex carbohydrate
EP2479263A1 (en) * 2011-01-20 2012-07-25 Jennewein Biotechnologie GmbH Novel Fucosyltransferases and their applications
US20120294840A1 (en) 2011-05-13 2012-11-22 Glycosyn LLC. Trustees of Boston College Use Of Purified 2'-Fucosyllactose, 3-Fucosyllactose and Lactodifucotetraose as Prebiotics
US20150231159A1 (en) 2012-09-14 2015-08-20 Abbott Laboratories Methods for increasing brain functionality using 2-fucosyl-lactose
KR101544184B1 (en) 2014-12-19 2015-08-21 서울대학교산학협력단 Variant Microorganism for Producing 2-Fucosyllactose and Method of Producing 2-Fucosyllactose by Using the Same
US20150290261A1 (en) 2014-04-10 2015-10-15 Mead Johnson Nutrition Company Methods of use for probiotics and prebiotics

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120122098A (en) * 2011-04-28 2012-11-07 주식회사 진켐 Fucosyltransferase Originated from Bacteroides fragilis
MX2016014807A (en) * 2014-05-15 2017-05-10 Glycosyn LLC Alpha (1,2) fucosyltransferase syngenes for use in the production of fucosylated oligosaccharides.
EP3233875B1 (en) * 2014-12-16 2022-10-05 Glycom A/S Separation of 2'-fl from a fermentation broth
CN105695537B (en) * 2016-02-29 2019-11-19 福建农林大学 A preparation method of glycosylated Enteromorpha oligosaccharides for lowering blood sugar and regulating intestinal flora
CN106434590A (en) * 2016-12-13 2017-02-22 福建农林大学 Fucosyltransferase, genetically engineered bacteria thereof and application

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040048331A1 (en) * 1998-11-04 2004-03-11 Governors Of The University Of Alberta, A Canada Corporation Alpha 1,2 fucosyltransferase
US20040058418A1 (en) * 2000-04-11 2004-03-25 Tetsuo Endo Alpha 1,2-fucosyltransferase and process for producing fucose-containing complex carbohydrate
EP2479263A1 (en) * 2011-01-20 2012-07-25 Jennewein Biotechnologie GmbH Novel Fucosyltransferases and their applications
WO2012097950A1 (en) 2011-01-20 2012-07-26 Jennewein Biotechnologie Gmbh Novel fucosyltransferases and their applications
KR20140032983A (en) 2011-01-20 2014-03-17 젠와인 바이오테크놀로지 게엠바하 Novel fucosyltransferases and their applications
US20120294840A1 (en) 2011-05-13 2012-11-22 Glycosyn LLC. Trustees of Boston College Use Of Purified 2'-Fucosyllactose, 3-Fucosyllactose and Lactodifucotetraose as Prebiotics
US20150231159A1 (en) 2012-09-14 2015-08-20 Abbott Laboratories Methods for increasing brain functionality using 2-fucosyl-lactose
US20150290261A1 (en) 2014-04-10 2015-10-15 Mead Johnson Nutrition Company Methods of use for probiotics and prebiotics
KR101544184B1 (en) 2014-12-19 2015-08-21 서울대학교산학협력단 Variant Microorganism for Producing 2-Fucosyllactose and Method of Producing 2-Fucosyllactose by Using the Same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
International Search Report for PCT/KR2018/014000 dated May 15, 2019 [PCT/ISA/210].
Sakai et al. Synthesis of ß-D-Fucosylglucose by ß-D-Glucosidase I of Bifidobacterium breve clb and Assimilation by Bifidobacteria. Agric. Biol. Chem., 53 (2), 313˜318, 1989. (Year: 1989). *
Sequence search result in the docket, 20211117_154508_us-16-765-359-2, Run on: Nov. 17, 2021. (Year: 2021). *
Written Opinion for PCT/KR2018/014000 dated May 15, 2019 [PCT/ISA/237].

Also Published As

Publication number Publication date
US20200338101A1 (en) 2020-10-29
KR101953375B1 (en) 2019-02-28
WO2019098706A3 (en) 2019-07-11
WO2019098706A2 (en) 2019-05-23
CN111629732A (en) 2020-09-04

Similar Documents

Publication Publication Date Title
US11504386B2 (en) Preparation method for various novel fucosyl oligosaccharides and use thereof
EP2081566B1 (en) Improved biological effects of compositions comprising rosmarinic acid
AU2016359483B2 (en) Polypeptides capable of producing glucans having alpha-1,2 branches and use of the same
US20250129185A1 (en) Enzymatic synthesis of soluble glucan fiber
US20170204442A1 (en) Enzymatic synthesis of soluble glucan fiber
US20170198323A1 (en) Enzymatic synthesis of soluble glucan fiber
CA2949269A1 (en) Enzymatic synthesis of soluble glucan fiber
EP3318263B1 (en) Antioxidant composition and composition for improvement of skin conditions
CN111246853A (en) Method for selecting probiotics
KR20190079514A (en) Cosmetic composition for skin moisturizing comprising fermented aloe as effective component
CN102333455A (en) Composition comprising chicoric acid and/or derivatives thereof
KR100926170B1 (en) Biopolymer produced by fermenting the extract of soybean with folic acid and a composition containing thereof
JP6096943B2 (en) Food and beverage composition
KR20180134601A (en) Functional Lactic Acid Bacteria Composition for Pregnant Woman
KR100987518B1 (en) Biopolymer produced by fermenting the extract of soybean with folic acid and a composition containing thereof
KR100987517B1 (en) Soybean fermented polymer material mixed with folic acid and composition comprising same
KR20130058388A (en) Antioxidative composition comprising fermented liriope platyphylla extract as an active ingredient
JP7029825B2 (en) Method for Producing Ceramide-Containing Composition
KR101003533B1 (en) Soybean fermented polymer material mixed with folic acid and composition comprising same
JP2016220617A (en) Method for producing ceramide-containing composition
CN119095949A (en) Novel Bifidobacterium bifidum HEM972 strain and composition for improving intestinal environment comprising the strain or its culture
HK1115805A (en) Improved biological effects of rosmarinic acid
KR20190028857A (en) Novel Lactococcus lactis R-camellia derived from red camellia and a composition for preventing hair loss or promoting hair growth containing the same

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

AS Assignment

Owner name: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIM, KYOUNG HEON;JIN, YONG-SU;YUN, EUN-JU;AND OTHERS;REEL/FRAME:052716/0041

Effective date: 20200507

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE